Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Ric Price shows that that primaquine is substantially less effective for preventing relapses of vivax malaria in real-world practice than is predicted by clinical efficacy trials and that this is a likely consequence of incomplete adherence to treatment.

Efforts to improve adherence to primaquine and to develop alternative drugs with shorter dosing regimens and greater patient tolerability are needed to achieve the significant public health benefits of P. vivax radical cure.

Read the full article